Maharashtra Orders State-Wide Audit of Blood Centres After FDA Shuts Two Facilities

The Maharashtra State Blood Transfusion Council (SBTC) has directed a comprehensive inspection of all government and private blood centres in the state, days after the Maharashtra Food and Drug Administration (FDA) ordered the closure of two facilities for serious regulatory violations.

In a circular issued by SBTC Director Dr Suhas Mohanalkar, blood transfusion officers have been instructed to inspect every blood centre under their jurisdiction. The inspections aim to verify compliance with technical standards, assess whether blood collection matches actual demand, and ensure adherence to the Drugs and Cosmetics Act, 1940, which classifies blood as a ‘drug’.

Officers are required to submit quarterly inspection reports to both the SBTC and concerned FDA officials. The circular also recommends action against facilities found violating prescribed norms, including possible suspension or cancellation of licences.

The move follows the FDA’s action against two blood centres, whose names have not been disclosed, for regulatory breaches. While specific violations were not detailed, the crackdown underscores the state’s focus on blood safety and quality standards.

Blood centres in Maharashtra must now comply with strict protocols for collection, processing, storage, and distribution. The circular reiterates that any deviation from standards could endanger patient safety, as contaminated or mismanaged blood can lead to serious health complications.

Health experts have welcomed the decision, noting that regular inspections are critical for maintaining trust in the blood supply chain. The SBTC has urged citizens to report any concerns about blood centre operations to local authorities.